North America Radiotherapy Market Outlook, 2031

Market Drivers

• High and rising cancer incidence across the region: The most fundamental driver of the North American radiotherapy market is the substantial and growing cancer burden. The American Cancer Society estimates approximately 1.9 million new cancer cases were diagnosed in the United States in 2023, sustaining persistent demand for radiation oncology services. Cancer is a growing cause of mortality worldwide, with millions of cases diagnosed each year. The expanding geriatric population contributes to this need, as the risk of cancer grows with age. The demand for radiotherapy is further amplified by the fact that approximately 50% of all cancer patients require radiotherapy at some point during their treatment. This sustained clinical demand ensures consistent requirements for radiotherapy equipment, software, and comprehensive maintenance services across the region.
• Advanced healthcare infrastructure and technology adoption: North America boasts some of the world's leading cancer research facilities and hospitals, which adopt and develop cuttingedge radiotherapy technologies. The region benefits from substantial healthcare spending from both the public and private sectors, allowing for significant investments in advanced medical equipment and treatment modalities. The adoption of advanced modalities including IMRT, IGRT, and SBRT is widespread, driven by strong reimbursement frameworks that support the utilization of precision radiotherapy technologies. The introduction of AIpowered radiotherapy systems by major players like Varian and Elekta is improving accuracy and patient outcomes. The United States is a market disruptor because of rapid technological advancement and government expenditure on healthcare.
• Favorable reimbursement frameworks and government initiatives: The United States benefits from a favorable reimbursement environment through Medicare, Medicaid, and commercial payers, which support the adoption of advanced radiotherapy technologies. Federal programs like the National Cancer Moonshot initiative aim to double the rate of improvements in cancer research and treatment, further accelerating the adoption of novel radiation therapies. The expansion of cancer screening programs across the region, such as breast cancer screening programs available in all Canadian provinces for women between 50 and 74 years of age, is likely to increase the number of cancer cases diagnosed, fostering a favorable environment for radiotherapy adoption.

Market Challenges

• High cost of radiotherapy equipment and treatment: A significant challenge facing the North American radiotherapy market is the high cost of advanced equipment and associated treatment delivery. The initial investment for technologies like proton therapy systems, MRguided LINACs, and robotic radiosurgery platforms is substantial, posing a barrier to entry for smaller healthcare providers and rural facilities. The operational costs associated with these systems are considerable, including specialized facility construction, rigorous quality assurance programs, and the need for highly trained medical physicists, engineers, and therapy staff. Healthcare providers face persistent budget pressure from Medicare, Medicaid, and commercial payers, which may not fully account for the additional expenses associated with premium technologies.
• Side effects and safety concerns associated with radiotherapy: Radiotherapy, while effective, is associated with adverse reactions that can impact patient quality of life and treatment adherence. Radiotherapy is responsible for the breakdown of DNA and the death of cancer cells, but the same effect is observed in healthy cells, leading to adverse reactions including fatigue, skin problems, hair loss, low blood counts, headaches, nausea, vomiting, hearing loss, and seizures. According to a study published by NCBI, the minimal tolerance dose of radiation therapy causes adverse reactions in approximately 5.0% of patients, while the maximum tolerance dose causes adverse effects in approximately 50.0% of therapy recipients within or after five years of radiotherapy. The increased risk of side effects can hamper market growth by influencing patient and physician treatment decisions.
• Workforce shortages in radiation oncology: The clinical engineering and radiation oncology workforce is aging across North America, and the supply of qualified medical physicists, radiation oncologists, and radiation therapists is not keeping pace with demand. The United States faces a structural shortage of biomedical engineers and clinical technicians, while Canada experiences geographic workforce distribution challenges. The aging workforce and limited new entrants create a structural need for external service partnerships and workforce development programs. This shortage limits the capacity for inhouse treatment programs and increases reliance on OEMs and service organizations.

Market Trends

• Shift toward precision radiotherapy and personalized medicine: A major trend shaping the North American radiotherapy market is the increasing movement toward precision radiotherapy and personalized medicine in cancer treatment. Customizing radiation doses and schedules based on genetic, phenotypic, and environmental factors that may impact treatment response is a component of personalized medicine approaches. By focusing on tailored patient care, healthcare practitioners can boost treatment efficacy and decrease the occurrence of adverse side effects. The number of personalized medications available in the US market grew from 132 in 2016 to 286 in 2019, making up 25% of all new pharmaceuticals authorized by the FDA a substantial increase from 5% in 2005. This growth in personalized medicine is boosting the radiotherapy market as it drives demand for precision delivery systems and advanced treatment planning software.
• Integration of artificial intelligence and digital technologies: The adoption of artificial intelligence in radiotherapy is accelerating across North America, with manufacturers introducing AIpowered systems that improve accuracy and patient outcomes. AI is being deployed to enhance treatment planning through automated contouring, dose optimization, and adaptive replanning, reducing the workload on clinicians and improving consistency across treatment teams. On the operational side, health systems are implementing enterprise asset management platforms that monitor equipment performance in real time, predict potential failures, and schedule maintenance proactively to avoid unplanned downtime. This shift toward predictive and datadriven service models is particularly important for highutilization equipment like linear accelerators.
• Expansion of proton therapy and advanced particle therapy centers: The United States is leading the expansion of proton therapy infrastructure, with over 40 operating centers and a 30% increase in utilization between 2020 and 2023. This trend reflects the growing clinical evidence supporting proton therapy for specific indications, including pediatric cancers, brain tumors, and head and neck cancers. The numerical and geographic expansion of proton treatment facilities has resulted in enhanced patient access as well as an exponential increase in the capacity to collect clinical data and participate in multicenter clinical studies. This trend is driving significant capital investment and creating new demand for specialized maintenance and service contracts.